CN103249730A - 丙型肝炎病毒抑制剂 - Google Patents
丙型肝炎病毒抑制剂 Download PDFInfo
- Publication number
- CN103249730A CN103249730A CN2010800703399A CN201080070339A CN103249730A CN 103249730 A CN103249730 A CN 103249730A CN 2010800703399 A CN2010800703399 A CN 2010800703399A CN 201080070339 A CN201080070339 A CN 201080070339A CN 103249730 A CN103249730 A CN 103249730A
- Authority
- CN
- China
- Prior art keywords
- condition
- nmr
- water
- analytical calculation
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC1(C)C=CC(c2c(*)nc(C3N(*)C(*)C(*)(*)*3)[n]2)=CC=C1 Chemical compound CC1(C)C=CC(c2c(*)nc(C3N(*)C(*)C(*)(*)*3)[n]2)=CC=C1 0.000 description 17
- KVAAJLXXJUXSQK-UHFFFAOYSA-N CC(C(O)OC)N Chemical compound CC(C(O)OC)N KVAAJLXXJUXSQK-UHFFFAOYSA-N 0.000 description 1
- FDYQKZWGYXWZMB-SZKDOGBVSA-N CC(C)[C@@H](C(N(CC1(CC1)C1)C1C1NC(c(cc2)ccc2C#Cc(cc2)ccc2-c2cnc(C(CC3(CC3)C3)N3C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)=CN1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CC1(CC1)C1)C1C1NC(c(cc2)ccc2C#Cc(cc2)ccc2-c2cnc(C(CC3(CC3)C3)N3C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)=CN1)=O)NC(OC)=O FDYQKZWGYXWZMB-SZKDOGBVSA-N 0.000 description 1
- HOPXFIWICCEWNV-SNVBAGLBSA-N CC(C)[C@H](C(CC1)CCC1(F)F)NC(OC)=O Chemical compound CC(C)[C@H](C(CC1)CCC1(F)F)NC(OC)=O HOPXFIWICCEWNV-SNVBAGLBSA-N 0.000 description 1
- ZJVJPPNOQCMEPI-SNVBAGLBSA-N CCN(C)[C@@H](C(O)=O)c1ccccc1 Chemical compound CCN(C)[C@@H](C(O)=O)c1ccccc1 ZJVJPPNOQCMEPI-SNVBAGLBSA-N 0.000 description 1
- ZWVBAHITHMYEMS-SECBINFHSA-N CCNC(N[C@@H](C(O)=O)c1ccccc1)=O Chemical compound CCNC(N[C@@H](C(O)=O)c1ccccc1)=O ZWVBAHITHMYEMS-SECBINFHSA-N 0.000 description 1
- XHWFCZDENNEGEL-AABYBPBRSA-N CN(C)C[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)ccc2Oc(cc2)ccc2-c2cnc([C@H](CCC3)N3C([C@@H](c3ccccc3)N(C)C)=O)[nH]2)[nH]1)=O)c1ccccc1 Chemical compound CN(C)C[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)ccc2Oc(cc2)ccc2-c2cnc([C@H](CCC3)N3C([C@@H](c3ccccc3)N(C)C)=O)[nH]2)[nH]1)=O)c1ccccc1 XHWFCZDENNEGEL-AABYBPBRSA-N 0.000 description 1
- CWLQUGTUXBXTLF-RXMQYKEDSA-N CN(CCC1)[C@H]1C(O)=O Chemical compound CN(CCC1)[C@H]1C(O)=O CWLQUGTUXBXTLF-RXMQYKEDSA-N 0.000 description 1
- AMAJHILKNLCWBU-BEJOJVBKSA-N COC(NC(C1CCOCC1)C(N([C@@H]([C@H]1C2)C1=C)[C@@H]2c1ncc(-c2cc(C#Cc3cc(/C(/N)=C/N=C(\C4)/C4(C[C@H]([C@@H]45)C4=C)N5C(C(C4CCOCC4)NC(OC)=O)=O)ccc3)ccc2)[nH]1)=O)=O Chemical compound COC(NC(C1CCOCC1)C(N([C@@H]([C@H]1C2)C1=C)[C@@H]2c1ncc(-c2cc(C#Cc3cc(/C(/N)=C/N=C(\C4)/C4(C[C@H]([C@@H]45)C4=C)N5C(C(C4CCOCC4)NC(OC)=O)=O)ccc3)ccc2)[nH]1)=O)=O AMAJHILKNLCWBU-BEJOJVBKSA-N 0.000 description 1
- ZZBHBQQKLLJFOW-UHFFFAOYSA-N COc1cc2ccnc(C#N)c2cc1 Chemical compound COc1cc2ccnc(C#N)c2cc1 ZZBHBQQKLLJFOW-UHFFFAOYSA-N 0.000 description 1
- VUQQDZRSKKRERE-UHFFFAOYSA-N COc1cccc2c(C(O)=O)nccc12 Chemical compound COc1cccc2c(C(O)=O)nccc12 VUQQDZRSKKRERE-UHFFFAOYSA-N 0.000 description 1
- OEPLXFQYVFZKPJ-UHFFFAOYSA-N N#Cc1nc(-c2ccc[o]2)c(cccc2)c2c1 Chemical compound N#Cc1nc(-c2ccc[o]2)c(cccc2)c2c1 OEPLXFQYVFZKPJ-UHFFFAOYSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-SSDOTTSWSA-N N[C@@H](C(O)=O)c1ccccc1 Chemical compound N[C@@H](C(O)=O)c1ccccc1 ZGUNAGUHMKGQNY-SSDOTTSWSA-N 0.000 description 1
- GEGZYFGIYOZVSB-UHFFFAOYSA-N O=C(CCl)c1ccc(COCc(cc2)ccc2C(CCl)=O)cc1 Chemical compound O=C(CCl)c1ccc(COCc(cc2)ccc2C(CCl)=O)cc1 GEGZYFGIYOZVSB-UHFFFAOYSA-N 0.000 description 1
- RFYCQJHCAPCSTA-UHFFFAOYSA-N OC(Cc1c(CCl)cccc1)=O Chemical compound OC(Cc1c(CCl)cccc1)=O RFYCQJHCAPCSTA-UHFFFAOYSA-N 0.000 description 1
- GOSVNXMOCBVLPW-UHFFFAOYSA-N OC(Cc1c(CN2CCOCC2)cccc1)=O Chemical compound OC(Cc1c(CN2CCOCC2)cccc1)=O GOSVNXMOCBVLPW-UHFFFAOYSA-N 0.000 description 1
- QEEBXPXPYKOARL-UHFFFAOYSA-N OC(c1ncc[n]1Cc1ccccc1)=O Chemical compound OC(c1ncc[n]1Cc1ccccc1)=O QEEBXPXPYKOARL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2010/050138 WO2012039717A1 (en) | 2010-09-24 | 2010-09-24 | Hepatitis c virus inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103249730A true CN103249730A (zh) | 2013-08-14 |
Family
ID=43037168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800703399A Pending CN103249730A (zh) | 2010-09-24 | 2010-09-24 | 丙型肝炎病毒抑制剂 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2619195A1 (pt) |
| JP (1) | JP5619289B2 (pt) |
| CN (1) | CN103249730A (pt) |
| BR (1) | BR112013008148A2 (pt) |
| CA (1) | CA2812699A1 (pt) |
| EA (1) | EA201370078A1 (pt) |
| MX (1) | MX2013002927A (pt) |
| WO (1) | WO2012039717A1 (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2455376T3 (en) | 2009-06-11 | 2015-03-02 | Abbvie Bahamas Ltd | Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| WO2011009084A2 (en) | 2009-07-16 | 2011-01-20 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
| CA2794145A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| EP2963034A1 (en) | 2010-08-26 | 2016-01-06 | RFS Pharma, LLC. | Potent and selective inhibitors of hepatitis c virus |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9073943B2 (en) | 2012-02-10 | 2015-07-07 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| NZ703448A (en) | 2012-06-04 | 2017-07-28 | Actelion Pharmaceuticals Ltd | Benzimidazole-proline derivatives |
| CN104703980B (zh) | 2012-10-10 | 2017-09-22 | 埃科特莱茵药品有限公司 | 属于[邻双(杂)芳基]‑[2‑(间双(杂)芳基)吡咯烷‑1‑基]甲酮衍生物的食欲素受体拮抗剂 |
| EP2970241A1 (en) | 2013-03-12 | 2016-01-20 | Actelion Pharmaceuticals Ltd. | Azetidine amide derivatives as orexin receptor antagonists |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| AU2014358766B2 (en) | 2013-12-04 | 2019-01-17 | Idorsia Pharmaceuticals Ltd | Use of benzimidazole-proline derivatives |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| MX2019011239A (es) | 2017-03-31 | 2019-10-21 | Syngenta Participations Ag | Composiciones fungicidas. |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010065668A1 (en) * | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| CN102448956A (zh) * | 2009-03-30 | 2012-05-09 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| AU2003261434A1 (en) | 2002-08-12 | 2004-02-25 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of hcv replication |
| US7420079B2 (en) | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
| US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| DE102004036971B4 (de) | 2004-07-30 | 2009-07-30 | Advanced Micro Devices, Inc., Sunnyvale | Technik zur Bewertung lokaler elektrischer Eigenschaften in Halbleiterbauelementen |
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP2010034721A (ja) * | 2008-07-28 | 2010-02-12 | Fujitsu Ltd | パケットキャプチャ装置，パケットキャプチャ方法およびパケットキャプチャプログラム |
| US8138215B2 (en) * | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
-
2010
- 2010-09-24 EP EP10761101.4A patent/EP2619195A1/en not_active Withdrawn
- 2010-09-24 WO PCT/US2010/050138 patent/WO2012039717A1/en active Application Filing
- 2010-09-24 CA CA2812699A patent/CA2812699A1/en not_active Abandoned
- 2010-09-24 CN CN2010800703399A patent/CN103249730A/zh active Pending
- 2010-09-24 EA EA201370078A patent/EA201370078A1/ru unknown
- 2010-09-24 BR BR112013008148A patent/BR112013008148A2/pt not_active IP Right Cessation
- 2010-09-24 MX MX2013002927A patent/MX2013002927A/es not_active Application Discontinuation
- 2010-09-24 JP JP2013530121A patent/JP5619289B2/ja not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010065668A1 (en) * | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| CN102448956A (zh) * | 2009-03-30 | 2012-05-09 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012039717A1 (en) | 2012-03-29 |
| CA2812699A1 (en) | 2012-03-29 |
| EP2619195A1 (en) | 2013-07-31 |
| JP2013537905A (ja) | 2013-10-07 |
| EA201370078A1 (ru) | 2013-11-29 |
| BR112013008148A2 (pt) | 2016-08-09 |
| MX2013002927A (es) | 2013-05-30 |
| JP5619289B2 (ja) | 2014-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102448956B (zh) | 丙型肝炎病毒抑制剂 | |
| CN103249730A (zh) | 丙型肝炎病毒抑制剂 | |
| CN102803249B (zh) | 丙型肝炎病毒抑制剂 | |
| CN102459250B (zh) | 丙型肝炎病毒抑制剂 | |
| CN102395579B (zh) | 丙型肝炎病毒抑制剂 | |
| CN102227407B (zh) | 丙型肝炎病毒抑制剂 | |
| CN102741242B (zh) | 丙型肝炎病毒抑制剂 | |
| CN103153986B (zh) | 丙型肝炎病毒抑制剂 | |
| CN102177141B (zh) | 作为丙型肝炎病毒抑制剂的联-1h-苯并咪唑 | |
| CN102143959B (zh) | 丙型肝炎病毒抑制剂 | |
| CN102459281B (zh) | 丙型肝炎病毒抑制剂 | |
| CN102712628B (zh) | 丙型肝炎病毒抑制剂 | |
| CN101998954B (zh) | 用作丙型肝炎病毒抑制剂的构象受限的联苯衍生物 | |
| CN102712623B (zh) | 丙型肝炎病毒抑制剂 | |
| CN102007122B (zh) | 作为丙型肝炎病毒抑制剂的咪唑基联苯基咪唑 | |
| CN101998952B (zh) | 丙型肝炎病毒抑制剂 | |
| CN101754966B (zh) | 丙型肝炎病毒抑制剂 | |
| CN102791693B (zh) | 丙型肝炎病毒抑制剂 | |
| CN107207507B (zh) | 1,3-噻唑-2-基取代的苯甲酰胺 | |
| TWI547480B (zh) | Ｃ型肝炎病毒抑制劑 | |
| CN102459239A (zh) | 丙型肝炎病毒抑制剂 | |
| CN102015692A (zh) | 丙型肝炎病毒抑制剂 | |
| CN101534829A (zh) | 丙型肝炎病毒抑制剂 | |
| CN104884455A (zh) | 丙型肝炎病毒抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130814 |